The incidence of invasive fungal infections (IFI) caused by unusual pathogens is on rise, partly driven by increased populations of immunocompromised patients. The emerging multidrug-resistant yeast pathogen Candida auris (Auris means "ear" in Latin) has been a serious threat and a source of concern as agents of healthcare-associated infections. Some strains of the isolates are multi-resistant to the main classes of conventional antifungal drugs. Moreover, their identification using standard laboratory protocols are hardly proved. Many of these strains have been mistaken to be other yeasts such as Rhodotorula glutinins, Saccharomyces cerevisiae or Candida heamulonii. In fact, specialized laboratory procedure is required for their proper identification such as molecular techniques based on sequencing the D1-D2 region of the 28s rDNA or Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF). Misidentification might result in inappropriate treatment. Furthermore, C. auris has the tendency to cause outbreaks in healthcare settings, as has already been reported from several countries worldwide.